Tag: NASDAQ: GERN

Business

Geron Corporation (NASDAQ: GERN) Proclaims Publication of IMbark Phase 2 information in Journal of Clinical Oncology

Geron Corporation (NASDAQ: GERN), a late-stage scientific biopharmaceutical company, today publicized the publication of information from the IMbark Phase 2 scientific test in the Journal of Clinical Oncology in a document entitled, “Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.” The publication […]